Evidence map›Paper›PMID 42426285›Full record

ArticleNature cancer2026

A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS-STING-type I IFN signaling in macrophages.

Xingwen Wang, Yi Zhang, Jiangwen Ma, Qingyu Lin, Zhenghang Wang, Guixue Hou, Yutong Wei, Minqiao Lu, Meiqi Wang, Tianyu Li and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xingwen Wang *School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.ORCID http://orcid.org/0000-0001-7416-142X
Yi Zhang *School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Jiangwen MaSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Qingyu LinSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Zhenghang WangSpace Environment Simulation Research Infrastructure, Harbin, China.
Guixue HouBGI-SHENZHEN, Shenzhen, China.ORCID http://orcid.org/0000-0003-0342-9593
Yutong WeiSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.ORCID http://orcid.org/0009-0002-2118-8623
Minqiao LuSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Meiqi WangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Tianyu LiSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Shanliang ZhengSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Wenxin ZhangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Yafan GongSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Tianqi GuanSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Hao LiuSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Xiaotian ZhangDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.ORCID http://orcid.org/0000-0001-6936-2622
Li LiThe third affiliated hospital of Harbin Medical University, Harbin, China.
Ying HuSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China. huying@hit.edu.cn.ORCID http://orcid.org/0000-0003-2469-5604

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82025027National Natural Science Foundation of China (National Science Foundation of China) 82472678
6 · The paper itself

Abstract

Immune checkpoint blockade has achieved remarkable success in cancer treatment; however, enhancing its efficacy remains a challenge. Here we identified an immunoregulatory micropeptide encoded by the long noncoding RNA USP30-AS1 gene, highly expressed in tumor-associated macrophages. The so-designated UEIS (USP30-AS1-encoded immune suppressor) drives macrophages toward a protumorigenic phenotype, thereby inhibiting antitumor T cell immunity. Mechanistically, UEIS is induced in macrophages by cGAS-STING-type I interferon signaling at a relatively late stage following tumoral DNA stimulation, and exerts a negative feedback regulation on the type I interferon signaling by forming biomolecular condensates with TBK1, thereby inhibiting its interaction with STING. Both an intrinsically disordered region and an alpha helix at the extreme N terminus of UEIS were essential for its function. A peptide designed to disrupt UEIS-TBK1 condensation successfully inhibited UEIS function in tumor-associated macrophages, leading to reduced tumor growth and increased response to immune checkpoint blockade. Thus, these findings highlight UEIS as a promising therapeutic target for cancer treatment.

Indexed as

Interferon Type IMacrophagesMembrane ProteinsNeoplasmsNucleotidyltransferasesRNA, Long NoncodingAnimalsCell Line, TumorCell ProliferationcGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseFemaleHumansMiceMicropeptidesProtein Serine-Threonine KinasescGAS protein, humancGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseInterferon Type IMembrane ProteinsMicropeptidesNucleotidyltransferasesProtein Serine-Threonine KinasesRNA, Long NoncodingSTING1 protein, humanSting1 protein, mouseSTING Protein

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.